TransmedicsTMDX
About: TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Employees: 728
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
49% more repeat investments, than reductions
Existing positions increased: 125 | Existing positions reduced: 84
1.14% more ownership
Funds ownership: 108.63% [Q3] → 109.78% (+1.14%) [Q4]
16% less funds holding
Funds holding: 365 [Q3] → 308 (-57) [Q4]
17% less call options, than puts
Call options by funds: $51.6M | Put options by funds: $62.5M
40% less first-time investments, than exits
New positions opened: 73 | Existing positions closed: 122
59% less capital invested
Capital invested by funds: $5.67B [Q3] → $2.3B (-$3.37B) [Q4]
90% less funds holding in top 10
Funds holding in top 10: 10 [Q3] → 1 (-9) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Oppenheimer Suraj Kalia 56% 1-year accuracy 10 / 18 met price target | 7%upside $130 | Outperform Maintained | 9 May 2025 |
Piper Sandler Matt O'Brien 50% 1-year accuracy 24 / 48 met price target | 3%upside $125 | Overweight Reiterated | 9 May 2025 |
Canaccord Genuity William Plovanic 43% 1-year accuracy 20 / 47 met price target | 14%downside $104 | Buy Maintained | 11 Mar 2025 |
Financial journalist opinion
Based on 29 articles about TMDX published over the past 30 days
